United States

Jnana Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Jnana Therapeutics Enters Collaboration with Roche to Discover Novel Medicines that Target Key Regulators of Cellular Metabolism

Lead Product(s): Undisclosed

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: $1,040.0 million Upfront Cash: $40.0 million

Deal Type: Collaboration July 21, 2020

Details:

Under the terms of the agreement, Jnana will partner with Roche on discovery and preclinical development for a broad set of targets across immunology and neuroscience, which Roche will further develop and commercialize exclusively.

Dragonfly Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Dragonfly Therapeutics Announces Collaboration with BMS to Develop Novel Therapeutic Candidates for M.S and Neuro-inflammation Targets

Lead Product(s): NK cell Engager Therapies

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Bristol-Myers Squibb

Deal Size: Undisclosed Upfront Cash: $55.0 million

Deal Type: Licensing Agreement July 06, 2020

Details:

Under the agreement, Dragonfly will grant Bristol Myers Squibb the option to license exclusive worldwide intellectual property rights to multiple candidates developed using Dragonfly's proprietary platform for multiple new targets.

SIGA Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

SIGA Announces Deliveries of Oral TPOXX® to HHS Valued at Approximately $32 Million

Lead Product(s): Tecovirimat

Therapeutic Area: Immunology Product Name: Tpoxx

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: BARDA

Deal Size: $414.0 million Upfront Cash: Undisclosed

Deal Type: Agreement June 25, 2020

Details:

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the deliveries of oral TPOXX® (tecovirimat) to the U.S. Department of Health and Human Services (HHS).

SIGA Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX®

Lead Product(s): Tecovirimat

Therapeutic Area: Immunology Product Name: Tpoxx

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: JPEO-CBRND

Deal Size: $23.0 million Upfront Cash: Undisclosed

Deal Type: Funding June 15, 2020

Details:

Funding will support work necessary to gain a potential label expansion from the U.S. FDA for TPOXX® (tecovirimat) for Post-Exposure Prophylaxis (PEP) in addition to the current approved labeling for the treatment of smallpox.

HotSpot Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

SR One fuels HotSpot's $65M B round to fund allosteric R&D

Lead Product(s): Undisclosed

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: S.R. One

Deal Size: $65.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing May 21, 2020

Details:

The Series B financing will support the advancement of HotSpot’s lead programs to the clinic, including protein kinase C (PKC-theta) antagonists for Th2 and T-reg driven autoimmune disease and S6 kinase (S6K) antagonists for rare metabolic disease.

Dyno Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Dyno Therapeutics Announces Presentations at 2020 American Society of Gene and Cell Therapy Conference

Lead Product(s): Synthetic AAV capsids Proteins

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 12, 2020

Details:

The presentation will highlight results from Dyno's study on Artificial intelligence powered design of synthetic AAV capsids without pre-existing immunity for the universal treatment of all patients.

Ventus Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Ventus Uncloaks with $60M to Target the Innate immune System

Lead Product(s): Undisclosed

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Versant Ventures

Deal Size: $60.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing May 06, 2020

Details:

Proceeds will be used to advance three pipeline programs and to expand the company’s structural immunology platform to pursue previously intractable drug targets.

Quench Bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases

Lead Product(s): Undisclosed

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: RA Capital Management

Deal Size: $50.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 27, 2020

Details:

The funding will support company's lead therapeutic approach that inhibits Gasdermin D, which has been recently discovered as a key target at the core of multiple inflammatory cell death pathways.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Jnana Therapeutics

Jnana Therapeutics Enters Collaboration with Roche to Discover Novel Medicines that Target Key Regulators of Cellular Metabolism

Dragonfly Therapeutics

Dragonfly Therapeutics Announces Collaboration with BMS to Develop Novel Therapeutic Candidates for M.S and Neuro-inflammation Targets

SIGA Technologies

SIGA Announces Deliveries of Oral TPOXX® to HHS Valued at Approximately $32 Million

SIGA Technologies

SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX®

HotSpot Therapeutics

SR One fuels HotSpot's $65M B round to fund allosteric R&D

Dyno Therapeutics

Dyno Therapeutics Announces Presentations at 2020 American Society of Gene and Cell Therapy Conference

Ventus Therapeutics

Ventus Uncloaks with $60M to Target the Innate immune System

Quench Bio

Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases